

Colorectal Cancer Pathways

Patient Name: _____

Date of Birth: _____

Member Number: _____

Treatment Start Date: _____

Pathology: _____

Stage: _____

Line of Therapy: __ Adjuvant/Post-Op __ 1st Line __ 2nd Line
__ 3rd Line __ 3rd Line+

ECOG Performance Status: _____ **ICD-10 Code:** _____

Biomarkers/Characteristics: (select all that apply)

k-ras genotype: __ Wild Type(WT) __ Mutant(MT)

Microsatellite instability: __ dMMR/MSI-H __ MSI-L __ Not reported

n-ras genotype: __ Wild Type(WT) __ Mutant(MT)

NTRK Fusion: __ Positive __ Negative __ Not Reported

BRAF status: __ Wild Type(WT) __ V600E Mutation __ V600K Mutation

Adjuvant Therapy | Limited to Colon Cancer Only

__ Capecitabine (Xeloda)*

__ **CAPOX:** capecitabine (Xeloda) and oxaliplatin (limited to 3 months duration)†

__ **FOLFOX:** fluorouracil (5-FU), leucovorin, and oxaliplatin

__ **FULV:** fluorouracil (5FU) and leucovorin*

Metastatic Disease | RAS Wild Type (WT) or Mutant (MT)‡ | First or Second Lines of Therapy (1st or 2nd Line)

__ Capecitabine (Xeloda)

__ **FOLFIRI ± bevacizumab:** fluorouracil (5FU), leucovorin, and irinotecan (Camptosar) with or without bevacizumab

__ **FOLFIRINOX ± bevacizumab:** fluorouracil (5FU), leucovorin, irinotecan (Camptosar), and oxaliplatin with or without bevacizumab

__ **mFOLFIRINOX[§] ± bevacizumab:** fluorouracil (5FU), leucovorin, irinotecan (Camptosar), and oxaliplatin with or without bevacizumab

__ **FOLFOX ± bevacizumab:** fluorouracil (5FU), leucovorin, oxaliplatin, with or without bevacizumab¶

__ **FOLFOXIRI ± bevacizumab:** fluorouracil (5FU), leucovorin, oxaliplatin, and irinotecan (Camptosar) with or without bevacizumab

__ **FULV ± bevacizumab:** fluorouracil (5FU) and leucovorin with or without bevacizumab

Metastatic Disease | RAS Wild Type (WT) AND BRAF Wild Type (WT) | First or Second Lines of Therapy (1st or 2nd Line)

__ **FOLFIRI + panitumumab:** fluorouracil (5FU), leucovorin, and irinotecan (Camptosar) with panitumumab (Vectibix)[§]

__ **FOLFOX + panitumumab:** fluorouracil (5-FU), leucovorin, and oxaliplatin with panitumumab (Vectibix)[§]

__ Irinotecan (Camptosar) and panitumumab (Vectibix)[§]

Metastatic Disease | MSI-H or dMMR | First or Second Lines of Therapy (1st or 2nd Line)

__ Pembrolizumab (Keytruda)^{||}

* These adjuvant pathways do not apply to patients with MSI-H (microsatellite instability-high) disease

† Limited to low-risk (T1-3, N1), stage III colon cancer only

‡ Exon 2 KRAS, non-exon 2 KRAS, and NRAS mutations; testing recommended for all patients with metastatic disease

§ Modified FOLFIRINOX: Bolus 5-FU not administered

|| Limit to one line of therapy

¶ Administered at a dose of 200 mg every 3 weeks OR 400 mg every 6 weeks per the FDA label OR 2 mg/kg (up to a maximum of 200 mg) every 3 weeks, as clinically appropriate

Bevacizumab administered at a dose of 5mg/kg

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered “on pathway.” However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.



8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Last review: 8/2/2022 | Effective date: 10/10/2022

Appropriate.Safe.Affordable
© 2022 AIM Specialty Health
9007-1022